Compare XFOR & LX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XFOR | LX |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | United States | China |
| Employees | 143 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.5M | 464.4M |
| IPO Year | N/A | 2017 |
| Metric | XFOR | LX |
|---|---|---|
| Price | $4.41 | $2.13 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 1 |
| Target Price | ★ $25.20 | $3.50 |
| AVG Volume (30 Days) | 495.0K | ★ 1.6M |
| Earning Date | 03-17-2026 | 05-20-2026 |
| Dividend Yield | N/A | ★ 17.52% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $3.24 |
| Revenue Next Year | $80.31 | $11.50 |
| P/E Ratio | ★ N/A | $2.08 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $2.02 |
| 52 Week High | $6.63 | $10.20 |
| Indicator | XFOR | LX |
|---|---|---|
| Relative Strength Index (RSI) | 58.40 | 28.30 |
| Support Level | $3.01 | N/A |
| Resistance Level | $4.83 | $2.73 |
| Average True Range (ATR) | 0.36 | 0.12 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 88.27 | 14.89 |
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
LexinFintech Holdings Ltd is an online consumer finance platform and a technology-driven service provider in China. The group is engaged in online direct sales services and online consumer finance services for its customers in the PRC. Geographically, it derives revenue from China.